Centogene N.V.

Equities

CNTG

NL0014040206

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 09:52:08 2024-03-28 am EDT 5-day change 1st Jan Change
0.725 USD +5.07% Intraday chart for Centogene N.V. +8.81% -39.17%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Centogene, Takeda Pharmaceutical Collaborate on Lysosomal Storage Disorders Diagnostics MT
Centogene N.V. Announces the Extension of an Ongoing Partnership with Takeda to Continue Providing Access to Genetic Testing for Patients with Lysosomal Storage Disorders CI
Centogene Explores Strategic Alternatives CI
Centogene N.V. and the Laboratory of Human Genetics of Infectious Diseases At Institut Imagine Announce Rare Disease Research Collaboration CI
Centogene N.V. and The Michael J. Fox Foundation for Parkinson's Research Announces Research Project to Validate Genetic Risk Factors of Parkinson's Disease Using Multiomics CI
Centogene N.V. Provides Earnings Guidance for the Full Year 2023 CI
Centogene N.V. Announces Changes to Supervisory Board CI
Centogene N.V.'s Frontotemporal Dementia Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone CI
Centogene, Saudi Arabia's Public Investment Fund Form JV MT
Centogene N.V. and Lifera Complete Strategic Joint Venture Transaction CI
Centogene N.V. Announces the Discovery of A New Form of Early-Onset Dystonia and Parkinsonism CI
Centogene N.V. Expands Multiomic Diagnostic Portfolio with Newly-Launched Transcriptomic Offering CI
Flemming Ornskov Decides to Step Down from His Role as a Member of the Supervisory Board of Centogene CI
Centogene N.V. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Centogene N.V. Reaffirms Revenue Guidance for the Year 2023 CI
Upcoming Payrolls Report Lifts Exchange-Traded Funds, Equity Futures Premarket Friday MT
Centogene N.V. Announces Publication Establishing Lyso-Gb1 as A Predictive Biomarker for Gaucher Disease Patients CI
Centogene Receives Non-Compliance Notice From Nasdaq MT
Centogene N.V. Announces Resignation of Berndt Modig from Supervisory Board CI
Centogene Regains Compliance With Nasdaq Listing Rules MT
Centogene Biodatabank Reveals Unique Genetic Variants in World's Largest Niemann-Pick Type C1 Disease Cohort CI
Centogene Teams Up With Lifera to Boost Access to Multiomic Testing in Saudi Arabia MT
Centogene N.V. and Lifera Enter Strategic Collaboration to Increase Access to Leading Data-Driven Multiomic Testing CI
Centogene N.V. announced that it expects to receive $30 million in funding from Lifera CI
Bettina Goerner Decides to Step Down as Chief Data Officer of Centogene N.V., Effective May 26, 2023 CI
Chart Centogene N.V.
More charts
Centogene N.V., is a commercial company. The company focuses on rare diseases, transforming clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The company's platform includes epidemiological, phenotypic, and genetic data reflecting a global population, as well as a biobank of blood samples from these patients. The company's pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The Company's Clinical Diagnostics segment provides targeted genetic sequencing and diagnostic services to patients through its distribution partners and customers, which are typically physicians, laboratories or hospitals.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.6377 EUR
Average target price
1.378 EUR
Spread / Average Target
+116.09%
Consensus
  1. Stock
  2. Equities
  3. Stock Centogene N.V. - Nasdaq
  4. News Centogene N.V.
  5. Centogene N : Credit Suisse Lowers Centogene's PT to $14 from $15 After Weaker-than-Expected Q1 Profitability, Keeps Outperform Rating